Skip to main content
. 2020 Jun 30;2020:5120230. doi: 10.1155/2020/5120230

Figure 1.

Figure 1

AChE inhibitors marketed for the treatment of AD (1-4) together with the NMDA receptor antagonist Memantine (5).